Financial News
ProMIS Neurosciences Inc. - Common Shares (NQ: PMN )
1.240
+0.010
(+0.82%)
Streaming Delayed Price
Updated: 12:57 PM EDT, Aug 16, 2024
Add to My Watchlist
All News about ProMIS Neurosciences Inc. - Common Shares
![](https://investorplace.com/wp-content/uploads/2021/04/wall-street-federal-hall.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/08/12/movers-image.jpeg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/07/26/xrdDAFqNaIkdw02-j153520640059868796-t230.jpeg?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/04/15/image20.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/04/15/image31_0.jpeg?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
Via GlobeNewswire
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
Via GlobeNewswire
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/01/19/image44.jpg?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
ProMIS Neurosciences Issues Letter to Shareholders
January 08, 2024
Via GlobeNewswire
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
ProMIS Neurosciences Announces Publication on Novel Target for ALS
December 20, 2023
Via GlobeNewswire
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
![](https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_0.jpeg?width=1200&height=800&fit=crop)
Benzinga's Top Ratings Upgrades, Downgrades For October 3, 2023
October 03, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.